Accuray Incorporated (ARAY) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Accuray Incorporated stock (ARAY) is currently trading at $0.38. Accuray Incorporated PS ratio (Price-to-Sales) is 0.10. Analyst consensus price target for ARAY is $2.52. WallStSmart rates ARAY as Sell.
- ARAY PE ratio analysis and historical PE chart
- ARAY PS ratio (Price-to-Sales) history and trend
- ARAY intrinsic value — DCF, Graham Number, EPV models
- ARAY stock price prediction 2025 2026 2027 2028 2029 2030
- ARAY fair value vs current price
- ARAY insider transactions and insider buying
- Is ARAY undervalued or overvalued?
- Accuray Incorporated financial analysis — revenue, earnings, cash flow
- ARAY Piotroski F-Score and Altman Z-Score
- ARAY analyst price target and Smart Rating
Accuray Incorporated
📊 No data available
Try selecting a different time range
Smart Analysis
Accuray Incorporated (ARAY) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, price/book, institutional own.. Concerns around market cap and peg ratio. Mixed signals suggest waiting for clearer direction before acting.
Accuray Incorporated (ARAY) Key Strengths (3)
Paying less than $1 for every $1 of annual revenue
Trading below book value, meaning the market prices it less than net assets
70.84% of shares held by major funds and institutions
Supporting Valuation Data
Accuray Incorporated (ARAY) Areas to Watch (7)
Company is destroying shareholder value
Earnings declining -96.20%, profits shrinking
Company is losing money with a negative profit margin
Near-zero operating margins, business under pressure
Very expensive relative to growth, significant premium
Micro-cap company with very limited liquidity and high volatility
Solid revenue growth at 16.80% per year
Supporting Valuation Data
Accuray Incorporated (ARAY) Detailed Analysis Report
Overall Assessment
This company scores 44/100 in our Smart Analysis, earning a D grade. Out of 10 metrics analyzed, 3 register as strengths (avg 10.0/10) while 7 fall into concern territory (avg 1.7/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales, Price/Book, Institutional Own.. Valuation metrics including Price/Sales (0.10), Price/Book (0.87) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, EPS Growth, Profit Margin. Some valuation metrics including PEG Ratio (29.49) suggest expensive pricing. Growth concerns include Revenue Growth at 16.80%, EPS Growth at -96.20%, which may limit upside. Profitability pressure is visible in Return on Equity at -70.30%, Operating Margin at 3.73%, Profit Margin at -8.15%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -70.30% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 16.80% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and EPS Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ARAY Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ARAY's Price-to-Sales ratio of 0.10x trades at a deep discount to its historical average of 3.35x (0th percentile). The current valuation is 100% below its historical high of 60.65x set in Feb 2007, and 5% above its historical low of 0.1x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~0.5x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Accuray Incorporated (ARAY) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Accuray Incorporated is a strong growth company balancing expansion with improving profitability. Revenue reached 437M with 17% growth year-over-year. The company is currently unprofitable, posting a -8.2% profit margin.
Key Findings
The company is unprofitable with a -8.2% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -17M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Debt management: total debt of 204M is significantly higher than cash (41M). Monitor refinancing risk.
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Accuray Incorporated.
Bottom Line
Accuray Incorporated offers an attractive blend of growth (17% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Accuray Incorporated(ARAY)
NASDAQ
HEALTHCARE
MEDICAL DEVICES
USA
Accuray Incorporated designs, develops and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body in the Americas, Europe, the Middle East, India, Japan, Africa and the rest of the Asia Pacific region. The company is headquartered in Sunnyvale, California.